Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512710-17-00

Acronym

RP3-301

Enrollment

Registered

2024-12-02

Start date

2022-11-22

Completion date

Unknown

Last updated

2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Greece, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026